scispace - formally typeset
Search or ask a question
Author

Albert A. Tuinman

Other affiliations: University of Tennessee
Bio: Albert A. Tuinman is an academic researcher from Arizona State University. The author has contributed to research in topics: Mass spectrometry & Peptide sequence. The author has an hindex of 4, co-authored 7 publications receiving 577 citations. Previous affiliations of Albert A. Tuinman include University of Tennessee.

Papers
More filters
Journal ArticleDOI
TL;DR: A new nomenclature is proposed that allows a precise and concise description of mass spectrometric fragments derived from peptides by specifically accommodating extended or unusual amino acid residues, cyclic- and cyclodepsipeptides, and residues contained in branches of the main chain.
Abstract: A new nomenclature is proposed that allows a precise and concise description of mass spectrometric fragments derived from peptides. The nomenclature differs from existing methods by specifically accommodating (1) extended or unusual amino acid residues, (2) cyclic- and cyclodepsipeptides, and (3) residues contained in branches of the main chain.

11 citations

Journal ArticleDOI
TL;DR: A convenient and reliable method for rapidly determining amino acid molecular ions is based on observations of sulfolane and glycerol for solution-phase secondary-ion mass spectrometry of underivatized amino acids.

7 citations

Journal ArticleDOI
TL;DR: In this article, a new nomenclature is proposed that allows a precise and concise description of mass spectrometric fragments derived from peptides, including extended or unusual amino acid residues, cyclic-and cyclodepsipeptides, and residues contained in branches of the main chain.
Abstract: A new nomenclature is proposed that allows a precise and concise description of mass spectrometric fragments derived from peptides. The nomenclature differs from existing methods by specifically accommodating (1) extended or unusual amino acid residues, (2) cyclic- and cyclodepsipeptides, and (3) residues contained in branches of the main chain.

Cited by
More filters
Journal ArticleDOI
TL;DR: This review covers the literature published in 2014 for marine natural products, with 1116 citations referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and other intertidal plants and microorganisms.

4,649 citations

Journal ArticleDOI
TL;DR: This paper briefly reviews the main existing and potential high-value products which can be derived from microalgae and considers their commercial development with a particular focus on the various aspects which need to be considered on the path to commercialisation.
Abstract: Microalgae (including the cyanobacteria) are established commercial sources of high-value chemicals such as β-carotene, astaxanthin, docosahexaenoic acid, eicosahexaenoic acid, phycobilin pigments and algal extracts for use in cosmetics. Microalgae are also increasingly playing a role in cosmaceuticals, nutraceuticals and functional foods. In the last few years, there has been renewed interest in microalgae as commercial sources of these and other high-value compounds, driven in part by the attempts to develop commercially viable biofuels from microalgae. This paper briefly reviews the main existing and potential high-value products which can be derived from microalgae and considers their commercial development with a particular focus on the various aspects which need to be considered on the path to commercialisation, using the experience gained in the commercialisation of existing algae products. These considerations include the existing and potential market size and market characteristics of the product, competition by chemically synthesised products or by ‘natural’ compounds from other organisms such as fungi, bacteria, higher plants, etc., product quality requirements and assurance, and the legal and regulatory environment.

1,193 citations

Journal ArticleDOI
TL;DR: The history of drug discovery from marine natural products is reviewed, and by describing selected examples, the factors that contribute to new discoveries and the difficulties associated with translating marine-derived compounds into clinical trials are examined.
Abstract: Drug discovery from marine natural products has enjoyed a renaissance in the past few years. Ziconotide (Prialt; Elan Pharmaceuticals), a peptide originally discovered in a tropical cone snail, was the first marine-derived compound to be approved in the United States in December 2004 for the treatment of pain. Then, in October 2007, trabectedin (Yondelis; PharmaMar) became the first marine anticancer drug to be approved in the European Union. Here, we review the history of drug discovery from marine natural products, and by describing selected examples, we examine the factors that contribute to new discoveries and the difficulties associated with translating marine-derived compounds into clinical trials. Providing an outlook into the future, we also examine the advances that may further expand the promise of drugs from the sea.

1,002 citations

Journal ArticleDOI
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.

976 citations

Journal ArticleDOI
Ravi V. J. Chari1
TL;DR: The antitumor activity of these targeted agents was superior to that of the antibodies alone or the standard anticancer drugs in human tumor xenograft models and opens the door to the future development of highly potent drugs that were too toxic on their own to be therapeutically useful.
Abstract: The therapeutic activity of most anticancer drugs in clinical use is limited by their general toxicity to proliferating cells, including some normal cells. Although, chemists continue to develop novel cytotoxic agents with unique mechanisms of action, many of these compounds still lack tumor selectivity and have not been therapeutically useful. Monoclonal antibodies that bind to specific markers on the surface of tumor cells offer an alternative therapy that is tumor specific and thus less toxic. Although highly selective, very few monoclonal antibodies are therapeutically useful since they only display modest cell killing activity. The linkage of monoclonal antibodies to highly cytotoxic drugs can be viewed as a means of (a) conferring higher tumor selectivity to cytotoxic drugs that are too toxic to be used on their own or (b) conferring cell killing power to monoclonal antibodies that are tumor-specific but not sufficiently cytotoxic. This Account provides a brief history of the development of antibody...

756 citations